Mid-term administration of tolvaptan improves renal function accompanied by dose-reduction in furosemide in aquaporin-defined responders

International Heart Journal

Volumn 56, Issue 6, 2015, Pages 686-687

  Imamura, Teruhiko ^a   Kinugawa, Koichiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 2; ARGIPRESSIN; CREATININE; FUROSEMIDE; TOLVAPTAN; AQUAPORIN; BENZAZEPINE DERIVATIVE; DIURETIC AGENT; VASOPRESSIN RECEPTOR ANTAGONIST;

CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; DRUG DOSE REDUCTION; HUMAN; HYPONATREMIA; KIDNEY FUNCTION; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; BLOOD; HEART FAILURE; KIDNEY FUNCTION TEST; MEDICATION THERAPY MANAGEMENT; METABOLISM; PATIENT SELECTION; URINE;

ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; AQUAPORINS; ARGININE VASOPRESSIN; BENZAZEPINES; DIURETICS; FUROSEMIDE; HEART FAILURE; HUMANS; KIDNEY FUNCTION TESTS; MEDICATION THERAPY MANAGEMENT; PATIENT SELECTION;

EID: 84948977367     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.15-298     Document Type: Letter

References (6)

1. Kinugawa K, Imamura T, Komuro I. Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients. Clin Pharmacol Ther 2013; 94: 449-51.
2. Matsue Y, Suzuki M, Seya M, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensatedheart failure in high-risk population. J Cardiol 2013; 61: 169-74.
3. Matsuzaki M, Hori M, Izumi T, Fukunami M. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 2011; 25: S33-45.
4. Imamura T, Kinugawa K, Fujino T, et al. Increased urine aquaporin- 2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J 2014; 78: 2240-9.
5. Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist-pharmacology and clinical trials. Cardiovasc Drug Rev 2007; 25: 1-13. (Review)
6. Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin- 2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 2006; 290: F273-8.